Citations

Mayo Clinic

Showing 10 of 108551 citations.

Lifestyle Medicine for the Prevention and Treatment of Pancreatitis and Pancreatic Cancer
Subramanian, Sruthi Kapliyil, Brahmbhatt, Bhaumik , Bailey, Jennifer M. , Mutha, Pritesh , Bailey-Lundberg, Jennifer M , Thosani, Nirav C

Diagnostics | March 14, 2024 | Volume: 14 | Issue: 6 | Pages: 614

10.3390/diagnostics14060614 | PMID 38535034 Get It

The incidence of pancreatitis and pancreatic cancer is on the upswing in the USA. These conditions often lead to higher healthcare costs due to the complex nature of diagnosis and the need for specialized medical interventions, surgical procedures, and prolonged medical management. The economic ramification encompasses direct healthcare expenses and indirect costs related to productivity losses, disability, and potential long-term care requirements. Increasing evidence underscores the importance of a healthy lifestyle in preventing and managing these conditions. Lifestyle medicine employs evidence-based interventions to promote health through six key pillars: embracing a whole-food, plant-predominant dietary pattern; regular physical activity; ensuring restorative sleep; managing stress effectively; removing harmful substances; and fostering positive social connections. This review provides a comprehensive overview of lifestyle interventions for managing and preventing the development of pancreatitis and pancreatic cancer.
Radiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial
Rades, Dirk , Lomidze, Darejan, Jankarashvili, Natalia , López‐Campos, Fernando , Navarro-Martín, Arturo , Šegedin, Barbara , Grošelj, Blaž , Staackmann, Christian, Kristiansen, Charlotte , Dennis, Kristopher , Schild, Steven E. , Cacicedo, Jon , Kristiansen, Charlotte , Schild, Steven

Cancers | March 14, 2024 | Volume: 16 | Issue: 6 | Pages: 1149

10.3390/cancers16061149 | PMID 38539484 Get It

Patients with metastatic epidural spinal cord compression (MESCC) and favorable survival prognoses may benefit from radiation doses exceeding 10 × 3.0 Gy. In a multi-center phase 2 trial, patients receiving 15 × 2.633 Gy (41.6 Gy10) or 18 × 2.333 Gy (43.2 Gy10) were evaluated for local progression-free survival (LPFS), motor/sensory functions, ambulatory status, pain, distress, toxicity, and overall survival (OS). They were compared (propensity score-adjusted Cox regression) to a historical control group (n = 266) receiving 10 × 3.0 Gy (32.5 Gy10). In the phase 2 cohort, 50 (of 62 planned) patients were evaluated for LPFS. Twelve-month rates of LPFS and OS were 96.8% and 69.9%, respectively. Motor and sensory functions improved in 56% and 57.1% of patients, and 94.0% were ambulatory following radiotherapy. Pain and distress decreased in 84.4% and 78.0% of patients. Ten and two patients experienced grade 2 and 3 toxicities, respectively. Phase 2 patients showed significantly better LPFS than the control group (p = 0.039) and a trend for improved motor function (p = 0.057). Ambulatory and OS rates were not significantly different. Radiotherapy with 15 × 2.633 Gy or 18 × 2.333 Gy was well tolerated and appeared superior to 10 × 3.0 Gy.
The Association among Hypothalamic Subnits, Gonadotropic and Sex Hormone Plasmas Levels in Alzheimer’s Disease
Ofori, Edward , Solis, Anette, Initiative, on behalf of the Alzheimer’s Disease Neuroimaging, Ofori, Edward , Solis, Anamaria, Punjani, Nahid , Initiative, on behalf of the Alzheimer’s Disease Neuroimaging

Brain Sciences | March 14, 2024 | Volume: 14 | Issue: 3 | Pages: 276

10.3390/brainsci14030276 | PMID 38539664 Get It

This study investigates the sex-specific role of the Hypothalamic–Pituitary–Gonadal axis in Alzheimer’s disease progression, utilizing ADNI1 data for 493 individuals, analyzing plasma levels of gonadotropic and sex hormones, and examining neurodegeneration-related brain structures. We assessed plasma levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone (P4), and testosterone (T), along with volumetric measures of the hippocampus, entorhinal cortex, and hypothalamic subunits, to explore their correlation with Alzheimer’s disease markers across different cognitive statuses and sexes. Significant cognitive status effects were observed for all volumetric measures, with a distinct sex-by-cognitive status interaction for hypothalamic volume, indicating a decrease in males but not in females across cognitive impairment stages. Regression analyses showed specific hypothalamic subunit volume related to hormone levels, accounting for up to approximately 40% of the variance (p < 0.05). The findings highlight sex differences in neurodegeneration and hormonal regulation, suggesting potential for personalized treatments and advancing the understanding of Alzheimer’s disease etiology.
The aged microenvironment impairs BCL6 and CD40L induction in CD4+ T follicular helper cell differentiation
Fisher, Jacob S. , Adán‐Barrientos, Irene , Kumar, Naveen , Lancaster, Jessica N. , Kumar, Naveen R, Lancaster, Jessica N

Aging Cell | March 14, 2024 | Volume: 23 | Issue: 6 | Pages: No page available

10.1111/acel.14140 | PMID 38481058 Get It

AbstractWeakened germinal center responses by the aged immune system result in diminished immunity against pathogens and reduced efficacy of vaccines. Prolonged contacts between activated B cells and CD4+ T cells are crucial to germinal center formation and T follicular helper cell (Tfh) differentiation, but it is unclear how aging impacts the quality of this interaction. Peptide immunization confirmed that aged mice have decreased expansion of antigen‐specific germinal center B cells and reduced antibody titers. Furthermore, aging was associated with accumulated Tfh cells, even in naïve mice. Despite increased numbers, aged Tfh had reduced expression of master transcription factor BCL6 and increased expression of the ectonucleotidase CD39. In vitro activation revealed that proliferative capacity was maintained in aged CD4+ T cells, but not the costimulatory molecule CD40L. When activated in vitro by aged antigen‐presenting cells, young CD4+ naïve T cells generated reduced numbers of activated cells with upregulated CD40L. To determine the contribution of cell‐extrinsic influences on antigen‐specific Tfh induction, young, antigen‐specific B and CD4+ T cells were adoptively transferred into aged hosts prior to peptide immunization. Transferred cells had reduced expansion and differentiation into germinal center B cell and Tfh and reduced antigen‐specific antibody titers when compared to young hosts. Young CD4+ T cells transferred aged hosts differentiated into Tfh cells with reduced PD‐1 and BCL6 expression, and increased CD39 expression, though they maintained their mitochondrial capacity. These results highlight the role of the lymphoid microenvironment in modulating CD4+ T cell differentiation, which contributes to impaired establishment and maintenance of germinal centers.
Does climate impact inflatable penile prosthesis infection (IPP) risk? Assessment of temperature and dew point on IPP infections
Barham, David W. , Pyrgidis, Nikolaos , Amini, Eliad, Hammad, Muhammed , Andrianne, Robert, Gross, Kelli, Hatzichristodoulou, Georgios , Hotaling, James M. , Hsieh, Tung‐Chin , Lentz, Aaron , Modgil, Vaibhav , Osmonov, Daniar , Park, Sung Hun , Pearce, Ian , Perito, Paul , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez‐Sarmiento, Alfredo, Simhan, Jay , Warner, J, Ziegelmann, Matthew , Yafi, Faysal A. , Gross, Martin , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Jones, James M , Hammad, Muhammed A M , Miller, Jake A. , Burnett, Arthur L. “Bud” , Jenkins, Lawrence C. , Jones, James M. , Renterghem, Koenraad van , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership)

The Journal of Sexual Medicine | March 14, 2024 | Volume: 21 | Issue: 5 | Pages: 500-504

10.1093/jsxmed/qdae023 | PMID 38481017 Get It

Abstract Background Variations in climate have been associated with a greater risk of surgical site infections, urinary tract infections, and changes in the skin microbiome; however, limited data exist on the impact of climate on inflatable penile prosthesis (IPP) infections. Aim We sought to evaluate the impact of climate on the risk of IPP infections in a large international, multicenter cohort. Methods We performed a multi-institutional, retrospective study of patients undergoing IPP surgery. We then evaluated whether the month or season, during which surgery was performed, affected device infections. Implant infections were defined as infections requiring device explantation. A univariate logistic regression analysis was undertaken. Outcomes Our primary outcome was implant infection. Results A total of 5289 patients with a mean age of 62.2 ± 10.8 years received IPP placement. There was a fairly even distribution of implants performed in each season. A total of 103 (1.9%) infections were recorded. There were 32 (31.1%) IPP infections in patients who underwent surgery in the summer, followed by 28 (27.2%) in the winter, 26 (25.2%) in the spring, and 17 (16.5%) in the fall. No statistically significant differences were recorded in terms of season (P = .19) and month (P = .29). The mean daily temperature (P = .43), dew point (P = .43), and humidity (P = .92) at the time of IPP placement was not associated with infection. Clinical Implications These findings provide reassurance to prosthetic urologists that infection reduction strategies do not need to be tailored to local climate. Strengths and Limitations Climate data were not directly recorded for each hospital, but rather based on the monthly averages in the city where the surgery was performed. Conclusion The climate at time of IPP placement and time of year of surgery is not associated with IPP infection risk.
Medical student non-modifiable risk factors and USMLE Step 1 exam score
Davison, Jenna , Taylor, Margot B., Bumsted, Tracy, Davison, Jenna M

Medical Education Online | March 14, 2024 | Volume: 29 | Issue: 1 | Pages: No page available

10.1080/10872981.2024.2327818 | PMID 38481113 Get It

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Fleischmann, Roy , Mysler, Eduardo , Greenwald, Maria , Ytterberg, Steven R. , Koch, Gary G., Bhatt, Deepak L. , Wang, Cunshan, Mikuls, Ted R. , Chen, All‐shine, Connell, Carol A., Woolcott, John , Menon, Sujatha, Chen, Yan , Lee, Kristen , Fleischmann, Roy , Mikuls, Ted R , Szekanecz, Zoltán , Bhatt, Deepak L , Charles‐Schoeman, Christina

Arthritis & Rheumatology | March 14, 2024 | Volume: 76 | Issue: 8 | Pages: 1218-1229

10.1002/art.42846 | PMID 38481002 Get It

Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. Methods Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient‐years) by 6‐month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. Results Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6‐month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m 2 , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. Conclusion Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Lenz, Heinz‐Josef , Cohn, Allen Lee, Kochenderfer, Mark D., Élez, Elena , Shao, Spencer H. , Deming, Dustin A. , Holdridge, Regan, Larson, Timothy , Chen, Eric X. , Ucar, Antonio, Cullen, Dana, Baskin-Bey, Edwina, Kang, Tong, Hammell, Amy B, Yao, Jin, Elez, Elena , Chen, Eric , Parikh, Aparna R. , Spigel, David R. , Yoshino, Takayuki , Holdridge, Regan C., Mahipal, Amit , Hammell, A., Yao, Jin, Tabernero, Josep

Journal for ImmunoTherapy of Cancer | March 14, 2024 | Volume: 12 | Issue: 3 | Pages: e008409

10.1136/jitc-2023-008409 | PMID 38485190 Get It

Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with standard therapies in patients with mCRC. Here, we present phase 2 results of nivolumab plus standard-of-care therapy (SOC; 5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) versus SOC in the first-line treatment of patients with mCRC (CheckMate 9X8). Methods CheckMate 9X8 was a multicenter, open-label, randomized, phase 2/3 trial. Eligible patients were at least 18 years of age with unresectable mCRC and no prior chemotherapy for metastatic disease. Patients were randomized 2:1 to receive nivolumab 240 mg plus SOC or SOC alone every 2 weeks. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors V.1.1. Secondary endpoints included PFS by investigator assessment; objective response rate (ORR), disease control rate, duration of response, and time to response, all by BICR and investigator assessments; overall survival; and safety. Preplanned exploratory biomarker analyses were also performed. Results From February 2018 through April 2019, 310 patients were enrolled, of which 195 patients were randomized to nivolumab plus SOC (n=127) or SOC (n=68). At 21.5-month minimum follow-up, PFS with nivolumab plus SOC versus SOC did not meet the prespecified threshold for statistical significance; median PFS by BICR was 11.9 months in both arms (HR, 0.81 (95% CI, 0.53 to 1.23); p=0.30). Higher PFS rates after 12 months (18 months: 28% vs 9%), higher ORR (60% vs 46%), and durable responses (median 12.9 vs 9.3 months) were observed with nivolumab plus SOC versus SOC. Grade 3–4 treatment-related adverse events were reported in 75% versus 48% of patients; no new safety signals were identified. Conclusions The CheckMate 9X8 trial investigating first-line nivolumab plus SOC versus SOC in patients with mCRC did not meet its primary endpoint of PFS by BICR. Nivolumab plus SOC showed numerically higher PFS rates after 12 months, a higher response rate, and more durable responses compared with SOC alone, with acceptable safety. Further investigation to identify subgroups of patients with mCRC that may benefit from nivolumab plus SOC versus SOC in the first-line setting is warranted. Trial registration number NCT03414983 .
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
McKinley, Blake , Coston, Tucker W, Starr, Jason S. , McKinley, Blake J , Starr, Jason

The Oncologist | March 13, 2024 | Volume: 30 | Issue: 1 | Pages: No page available

10.1093/oncolo/oyae034 | PMID 38478398 Get It

Abstract We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance to RET-targeted therapy. Proposed mechanisms of resistance include intrinsic resistance of the nuclear receptor co-activator 4-RET fusion to RET inhibition, the RET fusion representing a passenger alteration to another tumorigenic driver pathway and/or decreased efficacy of RET inhibition after platinum-based chemotherapy. Our patient’s clinical course highlights the fact that “actionable” genomic alterations do not always equate to patient benefit.